LCK and B-cell chronic lymphocytic leukemia: In addition, selective targeting of the Lck SH2 domain by short phospho-tyrosine peptide is sufficient to induce cell death in CLL cells, as is pharmacological inhibition of Lck with dasatinib (Fig. 3C and 3D).